The search for a vaccine to prevent infection with HIV began with the isolation of the virus [1, 2] . Although much of the effort in HIV vaccine development has been devoted to inducing T-cell immune responses, and T-cell immunity is still a desired participant in preventing and controlling HIV infection, the focus of HIV vaccine research has pivoted towards antibody responses since a correlation was reported in the RV144 clinical trial between reduced infection and specific antibody levels in noninfected vaccinees [3] [4] [5] . In parallel with the RV144 results, there was a technological revolution in the production of human monoclonal antibodies (mAbs) which has led to the isolation and characterization of a large number of potent and broadly reactive neutralizing antibodies (bnAbs) [6] [7] [8] [9] . Induction of these exceptional antibodies with vaccine candidates has been the overarching goal of most HIV vaccine researchers, although the obstacles are enormous given that these bnAbs are found in a very small proportion of HIV-infected individuals and are characterized by extensive somatic hypermutation [10, 11] . To date, no vaccine tested in humans or animals has induced bnAbs, and the modest but significant protection in RV144 was achieved in the absence of any detectable bnAbs. Indeed, in RV144 there was no correlation between neutralizing antibodies and reduced infection rates [3] .
Increasingly, antibody-mediated protective immunity has been associated with non-neutralizing, Fc-mediated antibody functions. Non-neutralizing antibodies play a role in protection from a number of viral pathogens including influenza, herpes, alphaviruses, flaviviruses, respiratory syncytial virus, and CMV [12] [13] [14] [15] . In addition, in RV144 there was a correlation between antibody-dependent cell-mediated cytotoxicity and high levels of specific antibodies when the level of IgA HIVspecific antibodies was low [3, 16, 17] . Other nonneutralizing antibody-dependent activities have been implicated in protection and control of HIV in humans as well as SIV and SHIV in non-human primates [3, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] .
In this issue of AIDS, immunogens are described that induced non-neutralizing antibodies which may play an important role in protection. Initially, this group showed that macaques infected intravenously with SIV mac239 Dnef induced plasma cells in the submucosa and ectopic tertiary lymphoid follicles of the ectocervix and vagina; these cells produced IgG antibodies reactive with gp41 trimers (gp41t) which were concentrated in the path of virus entry by neonatal Fc receptors (FcRn) in the vaginal epithelium [28, 29] . Now, Voss et al. [30] have designed and tested SIV gp41t immunogens. Upon immunization of rhesus macaques, gp41t-specific antibodies were induced which were detectable in serum and found complexed with FcRnþ cervical vaginal epithelium. These data add to those previously published by other groups showing that non-neutralizing antibodies in general [27, 31, 32] , and gp41-specific antibodies in particular [33] [34] [35] [36] , can mediate Fc-dependent biologic functions associated with anti-viral effects and protection. Of note, two of the mAbs used in the latter studies of Fcmediated effects (gp41-specific human mAbs 240-D and 246-D) were members of a category of human mAbs, Cluster I anti-gp41 mAbs, which targets the immunodominant region of the gp41 ectodomain and reacts with trimeric gp41 [37] [38] [39] .
The data indicating a protective role of gp41 Abs also suggest an explanation for how an early vaccine candidate (live, attenuated SIV mac239 Dnef ) may have provided robust protection against subsequent challenge with SIV. Significantly, the data reported in this issue may provide an alternative approach to the development of an HIV vaccine. Although this approach certainly does not rule out a role for neutralizing antibodies, it extends the many other studies cited above indicating that the exceptional bnAbs which have been the Holy Grail of HIV vaccine research may not be an absolute requirement for protection, and that other 'conventional' antibodies, which are more readily induced than bnAbs, may be adequate to provide protection against HIV. What remains is still a daunting task: to demonstrate conclusively that non-neutralizing antibodies such as the ones described in Voss et al. [30] can protect, or participate in protection. Such a demonstration would need to explain why non-neutralizing antibodies, such as the gp41t Abs described in this issue (which are present in the majority of HIV-infected individuals), do not protect HIV þ individuals from superinfection.
